Core Insights - Tevogen Bio Holdings Inc. is preparing to provide updates to stockholders ahead of its Annual Meeting scheduled for June 23, 2025, focusing on its innovative business model and strategic growth initiatives [1] Group 1: Portfolio Assets - The company will update investors on its portfolio assets, which include Tevogen Bio Oncology, Tevogen Bio Specialty Care, and Tevogen.AI, valued at over $10 billion as of October 2024 [2] Group 2: Corporate Highlights - Tevogen will detail two strategic initiatives: Tevogen.AI and Tevogen Generics & Biosimilars, alongside plans to expand its operational footprint with an upgraded headquarters [3] Group 3: Financial Market Dynamics - Management is monitoring stock dynamics, noting the impact of a limited tradable float and the growing institutional ownership, which reflects strong investor confidence and long-term holding patterns [4]

Financial Performance - Tevogen Bio reported a net loss of $10.4 million for the three months ended March 31, 2025, compared to a net loss of $11.3 million for the same period in 2024, primarily due to non-cash stock-based compensation expenses [136]. - The net loss for the three months ended March 31, 2025, was $10.4 million, compared to a net loss of $11.3 million for the same period in 2024 [156]. - Research and development expenses for the three months ended March 31, 2025, were $3.2 million, a decrease of 84.7% from $20.8 million for the same period in 2024 [157]. - General and administrative expenses for the three months ended March 31, 2025, were $7.2 million, down 17.7% from $8.7 million in the same period in 2024 [158]. - Cash used in operating activities for the three months ended March 31, 2025, was $3.3 million, compared to $2.2 million for the same period in 2024 [165][166]. Cash and Funding - As of March 31, 2025, Tevogen Bio had an accumulated deficit of $123.8 million and cash reserves of $2.0 million [136]. - As of March 31, 2025, the company had $2.0 million in cash, an increase from $1.3 million as of December 31, 2024 [163]. - The company raised aggregate gross proceeds of $24.0 million from the sale of convertible promissory notes since January 2021 [163]. - The company has drawn $3.0 million from a Loan Agreement with a remaining $27.0 million available for future financing [163]. - The company expects to utilize $8.0 million in grant funding from KRHP for ongoing operational expenses through March 31, 2026 [176]. - The company is exploring various funding strategies, including private placements and partnerships, to support operations [177]. Clinical Development - The first clinical product, TVGN 489, has completed a Phase 1 proof-of-concept trial with no dose-limiting toxicities observed, and secondary endpoints showed a rapid reduction in viral load [126]. - The company aims to commercialize TVGN 489 and other product candidates, expecting to incur expenses related to expanding research and development capabilities and building manufacturing infrastructure [141]. - The company plans to conduct clinical trials for TVGN 489 and other product candidates, which will require considerable financial resources [172]. - The company anticipates increased expenses related to commercialization if marketing approval for TVGN 489 is obtained [174]. Patent and Technology - Tevogen Bio's patent portfolio includes three issued U.S. patents related to TVGN 489, all expiring on December 9, 2040, and nine pending U.S. patent applications [130][131]. - Tevogen Bio's ExacTcell technology is designed to develop off-the-shelf T cell therapies with applications in infectious diseases and cancers [124]. Future Expectations - The company has not generated any revenue to date and does not expect to do so until marketing approval is obtained for its product candidates [141]. - The company expects general and administrative expenses to increase in the future to support ongoing research and development and potential commercialization efforts [149]. - The company expects to incur costs associated with operating as a public company, necessitating additional funding [174]. Obligations and Agreements - Total contractual obligations as of March 31, 2025, amount to $4,846,712, with $1,846,712 due within one year [179]. - The company has committed to a securities purchase agreement with the Patel Family for $6.0 million in Series C Preferred Stock [170]. - The company has not yet received $3.0 million of the $6.0 million purchase price for Series A-1 Preferred Stock [170]. - The company has entered into a Loan Agreement allowing for monthly draws of up to $1.0 million over 27 months, with a maximum loan amount of $36.0 million [171]. - The company has drawn an aggregate of $3.0 million under the Loan Agreement as of March 31, 2025, with an additional $0.5 million drawn in April 2025 [171].

Group 1 - Tevogen Bio Holdings Inc. has received inquiries from shareholders about transferring shares to the Direct Registration System (DRS) following a recent press release [1] - The company will provide step-by-step guidance next week for shareholders to register their shares directly with the transfer agent, Continental Stock Transfer & Trust [2] - Several of Tevogen's largest shareholders have chosen to hold their shares via DRS, indicating their confidence in this method of ownership [2]

Core Viewpoint - Tevogen Bio Holdings Inc. has signed a letter of intent with CD8 Technology Services LLC to establish a facility that will support its cell therapy manufacturing, emphasizing the importance of in-house manufacturing for operational efficiency and highlighting significant insider ownership at 74% [1]. Company Summary - Tevogen's CEO, Ryan Saadi, stated that in-house manufacturing is critical for operational efficiency [1]. - The company has a notable insider ownership of 74%, indicating a strong commitment to business discipline [1]. Industry Context - The agreement with CD8 is expected to enhance Tevogen's research and manufacturing capabilities, particularly in building GMP (Good Manufacturing Practice) capabilities at scale [2]. - The company aims to develop product candidates for treating infectious diseases and cancer, which aligns with trends in the healthcare and biopharmaceutical industries [2].

Core Viewpoint - Tevogen Bio Holdings Inc. informs shareholders about the differences between holding shares in Direct Registration System (DRS) accounts versus brokerage accounts, highlighting the benefits and drawbacks of each option [1]. Group 1: DRS Accounts - DRS accounts allow shares to be registered directly in the shareholder's name, providing direct control over the shares [2]. - Holding shares in DRS accounts may result in reduced transaction and account maintenance costs for shareholders [2]. Group 2: Brokerage Accounts - Brokerage accounts may offer greater access to investment tools and facilitate quicker selling of shares compared to DRS accounts [2]. - Investors may incur costs associated with transferring shares in and out of brokerage accounts [2]. Group 3: Additional Information - For further details regarding the differences between DRS and brokerage accounts, shareholders are encouraged to contact the Company's transfer agent, Continental Stock Transfer & Trust [3].

Reflects business philosophy of commercial success through patient accessibilityRecently executed agreement with CD 8 Technology Services LLC providing up to $50 million for Company’s dedicated R&D and manufacturing facility; no impact on shareholder equity WARREN, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5- ...

Core Viewpoint - Tevogen Bio Holdings Inc. will hold its 2025 annual meeting of stockholders via live webcast on June 23, 2025, where stockholders will vote on the re-election of two directors and the ratification of the independent accounting firm [1] Group 1 - Stockholders of record as of April 30, 2025, are encouraged to participate in the voting process, with proxy materials to be distributed in accordance with SEC regulations [2] - The Company plans to disclose the voting results on a Form 8-K after the Annual Meeting [3] - A proxy statement will be filed with the SEC, which stockholders are urged to read carefully as it will contain important information about the Company and the Annual Meeting [4] Group 2 - Stockholders can obtain free copies of the proxy statement and other SEC filings from the SEC's website or the Company's Investor Relations page [5] - The Company and its directors and executive officers may be considered participants in the proxy solicitation, with relevant information to be included in the proxy statement [6]

Core Insights - Tevogen Bio has entered into an agreement with CD8 Technology Services for the development and/or acquisition of a turn-key facility to support pre-clinical research and GMP cell therapy production capabilities [1][2] - The agreement aims to accelerate development timelines, maintain operational agility, and control costs, addressing capital barriers typically faced in building GMP capabilities at scale [2][3] - The initial term of the agreement is 12 months, with automatic renewal, aligning with previously announced topline forecasts [2][6] Company Strategy - Tevogen Bio will provide primary staff and operations for the new facility, which is a significant step in expanding its infrastructure to support its pipeline of off-the-shelf, genetically unmodified CD8+ T cell therapeutics [3] - The agreement formalizes a previously announced letter of intent and is associated with Dr. Manmohan Patel, who owns more than 5% of the company's common stock [3] Future Outlook - Specific details regarding the facility, including scope of work, costs, and timelines, will be outlined in future work orders [3][6] - The agreement is expected to facilitate in-house cell therapy production capabilities, aligning with the company's long-term strategic goals [6]

Core Insights - Tevogen Bio has entered into an agreement with CD8 Technology Services LLC to develop a turn-key facility for in-house pre-clinical research and GMP cell therapy production capabilities [2][3] - The agreement is part of Tevogen Bio's long-term strategy to enhance development timelines, maintain operational flexibility, and control costs [3] - This milestone is seen as a significant step in expanding Tevogen Bio's infrastructure to support its pipeline of off-the-shelf, genetically unmodified CD8+ T cell therapeutics [4] Agreement Details - The agreement has an initial term of 12 months and will automatically renew, aligning with previously announced topline forecasts [3] - Tevogen Bio will provide the primary staff and operations for the facility, which is expected to help overcome capital barriers typically faced in building GMP capabilities at scale [3][4] - Specific details regarding the facility, including scope of work, costs, and timelines, will be outlined in future work orders [4] Leadership Commentary - Ryan Saadi, CEO of Tevogen Bio, emphasized the importance of this agreement in advancing the company's mission to help patients and in recognizing long-term shareholders [4]

Core Insights - Tevogen Bio Holdings Inc. has commissioned Databricks, Inc. to enhance the development of its AI-driven target prediction model, PredicTcell, aimed at precision immunotherapy [1][2] - The collaboration will focus on modeling immunologically active HLA+ peptide complexes and predicting T cell receptor (TCR) engagement, utilizing the ExacTcell™ platform [2] - This initiative represents a significant step in Tevogen's AI strategy, which is designed to transform precision medicine [3] Company Overview - Tevogen is dedicated to providing innovative and affordable healthcare solutions, operating through three strategic pillars: Tevogen Bio, Tevogen.AI, and Tevogen Generics [3] - Tevogen Bio focuses on genetically unmodified precision T cell therapies, while Tevogen.AI leverages AI for drug discovery and healthcare optimization [3] - The company possesses all key intellectual property and is led by a team with extensive experience in drug development and global product launches [3] Strategic Partnerships - Databricks will supply a dedicated data engineering team and expertise in data and AI systems to support the development of PredicTcell [2][6] - Microsoft Research is also contributing digital infrastructure and AI expertise to bolster the initiative [6]